Goldline Pharmaceutical Limited (BOM:544759)

Market Cap	373.44M
Revenue (ttm)	311.98M +29.9%
Net Income	41.17M +1,141.3%
EPS	5.97 +978.4%
Shares Out	9.60M
PE Ratio	6.52
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	255,000
Open	40.45
Previous Close	38.90
Day's Range	39.00 - 40.45
52-Week Range	33.00 - 60.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 8, 2026

About Goldline Pharmaceutical

Goldline Pharmaceutical Limited engages in marketing of pharmaceutical products under the Goldline brand in India. It offers goldline pharma, goldline cardinal, goldline aayushman, goldline inLife, and goldline wellness. The company serves physicians, orthopedics, ENT, chest physicians, general and specialty surgery, gastroenterology, neurology, urology, endocrinologists, cardiologists, general physicians, pediatricians, child specialists, neonatologists, intensivists, critical care consultants, and super specialty surgeons. It sells its produc...

• Industry: Drugs, Drug Proprietaries, and Druggists' Sundries
• Founded: 2004
• Employees: 126
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 544759

Financial Performance

In fiscal year 2026, Goldline Pharmaceutical's revenue was 311.98 million, an increase of 11.20% compared to the previous year's 280.56 million. Earnings were 41.17 million, an increase of 45.26%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 25, 2026

Data Sources Report a data error